Skip to main content
Clinical Trials/NCT03728569
NCT03728569
Terminated
Early Phase 1

Skin Barrier Dysfunction and the Role of Skin Barrier Restoration on Cutaneous and Systemic Inflammation in the Aged Population

University of Michigan1 site in 1 country14 target enrollmentMay 16, 2018

Overview

Phase
Early Phase 1
Intervention
Not specified
Conditions
Cutaneous Inflammation
Sponsor
University of Michigan
Enrollment
14
Locations
1
Primary Endpoint
Change in skin hydration status in aged and young subjects
Status
Terminated
Last Updated
4 years ago

Overview

Brief Summary

The objective of this exploratory study is to gain an understanding of cutaneous and systemic inflammation and how restoration of the skin barrier through the use of moisturizer may restore the skin barrier function and reduce systemic inflammation in elderly humans compared to the young. The exploratory study will consist of three visits per subject. Subjects will be instructed to apply a moisturizer (Vanicream Moisturizing Skin Cream) over the entire skin surface from the neck down twice daily for up to 30 days.

Registry
clinicaltrials.gov
Start Date
May 16, 2018
End Date
February 1, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Gary Fisher

Professor

University of Michigan

Eligibility Criteria

Inclusion Criteria

  • Aged group (\>70 years old)
  • In good general health
  • Body mass index (BMI) preferably in the healthy range (approximately 25 kg/m2) and no greater than 30 kg/m2
  • Fitzpatrick skin types I-V
  • Disrupted skin barrier defined as transepidermal water loss (TEWL) \>5 g/m2/h on the upper arms or \>3 g/m2/h on the buttocks
  • Clinical signs of skin dryness as determined by the investigator.
  • No disease states or physical conditions that would impair evaluation of the biopsy sites
  • Signed, written and witnessed informed consent form
  • Willing to comply with study procedures
  • Young group (18-30 years old)

Exclusion Criteria

  • Pregnant or lactating women or women contemplating pregnancy for the duration of the protocol (determined by self-report; if subjects are unsure of their pregnancy status, they will be excluded).
  • Frailty as determined by research study nurse
  • History of inflammatory skin conditions such as psoriasis or atopic dermatitis.
  • History of uncontrolled inflammatory or autoimmune disease.
  • History of keloids or any other condition that would complicate wound healing
  • History of allergic reactions to local lidocaine
  • Frequent nonsteroidal anti-inflammatory drug (NSAID) use (not including low dose aspirin) and unwilling/unable to discontinue NSAIDS for 2 weeks prior to enrollment to the end of the study.
  • Systemic steroids (excluding inhaled steroids for asthma) and unwilling/unable to discontinue systemic steroids for 3 weeks prior to enrollment to the end of the study.
  • Topical corticosteroid use within 2 weeks of enrollment.
  • Topical immunomodulation use such as calcineurin inhibitors within 2 weeks of enrollment

Outcomes

Primary Outcomes

Change in skin hydration status in aged and young subjects

Time Frame: up to 30 days

Trans-epidermal water loss (TEWL) will be performed on the upper arm and buttocks at Visits 1 and 2. This instrument will measure the amount of water that is lost through the skin. The change in skin hydration status in each subject will be assessed and compared between groups.

Study Sites (1)

Loading locations...

Similar Trials